152 related articles for article (PubMed ID: 11989589)
1. Is an antiemetic prophylactic treatment needed for patients submitted to consecutive days of 5-fluorouracil? An observational study.
Tumori; 2001; 87(6):379-82. PubMed ID: 11989589
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
[TBL] [Abstract][Full Text] [Related]
3. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
[TBL] [Abstract][Full Text] [Related]
4. Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):619-25. PubMed ID: 10348292
[TBL] [Abstract][Full Text] [Related]
5. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.
Ann Oncol; 1998 Jul; 9(7):759-65. PubMed ID: 9739443
[TBL] [Abstract][Full Text] [Related]
6. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
7. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
8. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
Chan A; Tan SH; Low XH; Yap KY
Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.
Pastore D; Bruno B; Carluccio P; De Candia MS; Mammoliti S; Borghero C; Chierichini A; Pavan F; Casini M; Pini M; Nassi L; Greco R; Tambaro FP; Stefanoni P; Console G; Marchesi F; Facchini L; Mussetti A; Cimminiello M; Saglio F; Vincenti D; Falcioni S; Chiusolo P; Olivieri J; Natale A; Faraci M; Cesaro S; Marotta S; Proia A; Donnini I; Caravelli D; Zuffa E; Iori AP; Soncini E; Bozzoli V; Pisapia G; Scalone R; Villani O; Prete A; Ferrari A; Menconi M; Mancini G; Gigli F; Gargiulo G; Bruno B; Patriarca F; Bonifazi F
Ann Hematol; 2020 Apr; 99(4):867-875. PubMed ID: 32036421
[TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T
BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107
[TBL] [Abstract][Full Text] [Related]
11. Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.
Ann Oncol; 1997 Jun; 8(6):561-7. PubMed ID: 9261525
[TBL] [Abstract][Full Text] [Related]
12. Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: antiemetic prescriptions and incidence of emesis.
Tumori; 2004; 90(1):103-6. PubMed ID: 15143981
[TBL] [Abstract][Full Text] [Related]
13. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
Hesketh PJ; Sanz-Altamira P; Bushey J; Hesketh AM
Support Care Cancer; 2012 May; 20(5):1043-7. PubMed ID: 21553313
[TBL] [Abstract][Full Text] [Related]
16. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
17. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.
J Clin Oncol; 1995 Sep; 13(9):2417-26. PubMed ID: 7666102
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
Sigsgaard T; Herrstedt J; Christensen P; Andersen O; Dombernowsky P
Support Care Cancer; 2000 May; 8(3):233-7. PubMed ID: 10789966
[TBL] [Abstract][Full Text] [Related]
20. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
